Physician profile
Narayan Neupane
NPI 1255578878
$10,174.53
in general payments reported to CMS, 2019-2025
40 companies · $3,517 in 2025
The $3,517 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2021: $641 · 2022: $523 · 2023: $1,095 · 2024: $3,827 · 2025: $3,517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,083 · Travel and Lodging: $2,856 · Education: $2,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,083.22 |
| Travel and Lodging | $2,855.57 |
| Education | $2,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,705.18 | 2025 | |
| Medtronic, INC. | $1,529.99 | 2022-2024 | Illumisite |
| Inspire Medical Systems, INC. | $1,260.31 | 2023-2025 | Inspire |
| Olympus Corporation of The Americas | $976.10 | 2024 | Single Use Suction Valve (Sterile) |
| Pulmonx Corporation | $821.54 | 2019-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Glaxosmithkline, LLC. | $372.40 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $339.81 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.40 | 2019-2025 | Ofev, Jascayd |
| Actelion Pharmaceuticals US, INC. | $195.00 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| United Therapeutics Corporation | $177.97 | 2022-2024 | Tyvaso |
| Genzyme Corporation | $151.00 | 2019-2025 | |
| Insmed, INC. | $143.53 | 2019-2025 | Arikayce, Brinsupri |
| Verona Pharma, INC. | $127.09 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $108.91 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Merck Sharp & Dohme LLC | $107.09 | 2023-2025 | Zerbaxa, Winrevair |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $100.76 | 2023-2025 | Tezspire |
| Pfizer INC. | $81.40 | 2019-2024 | |
| Philips North America LLC | $76.25 | 2019 | |
| 3b Medical, INC. | $57.23 | 2025 | Luna |
| Takeda Pharmaceuticals U.S.A., INC. | $50.31 | 2023-2024 | Glassia |
| Baxter Healthcare | $48.13 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Jazz Pharmaceuticals INC. | $46.96 | 2019-2023 | |
| Insulet Corporation | $45.37 | 2019-2021 | |
| Mylan Specialty L.P. | $43.52 | 2022-2024 | Yupelri |
| Mallinckrodt Enterprises LLC | $42.43 | 2019 | |
| Harmony Biosciences LLC | $40.00 | 2022-2023 | Wakix |
| Tactile Systems Technology INC | $37.59 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Csl Behring | $34.20 | 2025 | Hizentra |
| Axsome Therapeutics, INC. | $27.86 | 2023 | Sunosi |
| Avadel Cns Pharmaceuticals, LLC | $21.65 | 2025 | Lumryz |
| Novartis Pharmaceuticals Corporation | $17.23 | 2025 | |
| Paratek Pharmaceuticals, INC. | $17.14 | 2019 | |
| Circassia INC. | $16.51 | 2019 | |
| Ani Pharmaceuticals, INC. | $15.86 | 2024 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $15.45 | 2019 | |
| Electromed, INC. | $15.24 | 2024 | Smartvest |
| Advanced Respiratory, INC | $14.00 | 2019 | |
| Genentech USA, INC. | $13.20 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.92 | 2019 | |
| Sanofi Pasteur INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narayan Neupane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.